New triple therapy shows promise for hard-to-treat bile duct cancer
NCT ID NCT06859684
First seen Mar 10, 2026 · Last updated May 10, 2026 · Updated 9 times
Summary
This study tests a new first-line treatment for people with advanced bile duct cancer that cannot be removed by surgery. The treatment combines chemotherapy delivered directly to the liver (HAIC) with two drugs: durvalumab (an immunotherapy) and lenvatinib (a targeted therapy). The goal is to shrink tumors and improve survival. About 25 participants will take part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DURVALUMAB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.